[Neoadjuvant therapy for esophageal cancer - indication and efficacy].
Some approaches such as adjuvant chemotherapy, neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy have been tried to improve the efficacy of treatment for resectable esophageal cancer patients. The usefullness of neoadjuvant chemotherapy, has remained a matter of controversy. However, there is a report from JCOG9907 in Japan that two courses of neoadjuvant 5-FU/CDDP improved the survival of esophageal squamous cell cancer patients. Neoadjuvant chemoradiotherapy has not had a consistent evaluation because of the varying results of each trial. But from the results of meta-analysis and CALGB9781, the neoadjuvant chemoradiotherapy called "trimodality therapy" has been a standard treatment in the United States. We should evaluate whether there would be similar effectiveness in Japan, where the histology and operative approach are different. Some approaches such as DNA microarray and proteomics, which can predict the treatment effect, are being tried.
Kato
Ken
K
Gastrointestinal Oncology Division, National Cancer Center Hospital, Tsukiji, Tokyo, Japan.
Hamaguchi
Tetsuya
T
Yamada
Yasuhide
Y
Shirao
Kuniaki
K
Shimada
Yasuhiro
Y
D004938:Esophageal Neoplasms / Q000628:therapy*; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*